相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2007
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
• Organovo's FXR314 showed statistically significant reduction in liver fat content in MASH patients compared to placebo in a Phase 2 trial. • The study demonstrated a favorable safety profile for FXR314, with significantly lower pruritus rates than other FXR agonists. • Improvements in hepatocellular damage and liver function were observed based on serological measures, without worsening of liver fibrosis. • FXR314 represents a promising oral therapeutic option for MASH, with potential for further evaluation due to its intestinal activating specificity.
• Organovo's FXR314 showed a statistically significant reduction in liver fat content compared to placebo in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). • The Phase 2 trial demonstrated that 29.2% and 32.2% of patients receiving 3 mg and 6 mg doses of FXR314, respectively, experienced over a 30% reduction in liver fat fraction. • FXR314 was well-tolerated, with a safety profile indicating lower pruritus rates and no significant increases in LDL-C levels, supporting further evaluation for MASH treatment. • The drug's unique profile and specificity make it a promising candidate for metabolic liver disease and oncology applications, according to Dr. Eric Lawitz.
